(19)
(11) EP 4 584 299 A2

(12)

(88) Date of publication A3:
16.01.2025

(43) Date of publication:
16.07.2025 Bulletin 2025/29

(21) Application number: 23928994.5

(22) Date of filing: 03.09.2023
(51) International Patent Classification (IPC): 
C07K 16/44(2006.01)
A61P 25/36(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/70; C07K 16/44; C07K 2317/22; C07K 2317/569; C07K 2317/92; A61P 25/36
(86) International application number:
PCT/US2023/031942
(87) International publication number:
WO 2024/228717 (07.11.2024 Gazette 2024/45)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 07.09.2022 US 202263404495 P

(71) Applicant: Quantitative Biosciences, Inc.
San Diego, CA 92121 (US)

(72) Inventors:
  • CSICSERY, Nicholas, Sigmund
    San Diego, CA 92131 (US)
  • FERRY, Michael, Stephen
    San Diego, CA 92127 (US)
  • COOKSON, Scott, Warren
    Encinitas, CA 92024 (US)
  • COOKSON, Natalie, Anne
    Encinitas, CA 92024 (US)
  • MATHER, William, H.
    Encinitas, CA 92024 (US)

(74) Representative: Latscha Schöllhorn Partner AG 
Grellingerstrasse 60
4052 Basel
4052 Basel (CH)

   


(54) FENTANYL-SPECIFIC SINGLE VARIABLE-DOMAIN ANTIBODIES AND USE IN A CONTINUOUS AGGLUTINATION ASSAY